Integra LifeSciences reported second-quarter 2025 revenues of $415.6 million, a slight decrease of 0.6% year-over-year. GAAP EPS was significantly impacted by a $511 million goodwill impairment charge, resulting in a net loss of $(484.1) million and diluted EPS of $(6.31). However, adjusted EPS was $0.45, meeting the top end of their guidance. The company highlighted strong demand for neurosurgery and tissue technology products and progress on their Compliance Master Plan.
Second quarter revenues reached $415.6 million, exceeding guidance, though representing a 0.6% decrease on a reported basis year-over-year.
GAAP diluted EPS was $(6.31), primarily due to a $511 million goodwill impairment charge, while adjusted diluted EPS was $0.45, at the high end of the guidance range.
The company reported a GAAP net loss of $(484.1) million, a significant decline from a net loss of $(12.4) million in the prior year, largely due to the impairment charge.
Integra LifeSciences generated $8.9 million in cash flow from operations during the quarter, and maintained total liquidity of approximately $1.14 billion.
For Q3 2025, Integra LifeSciences expects revenues between $410 million and $420 million, with adjusted EPS in the range of $0.40 to $0.45. The full-year 2025 revenue guidance has been updated to $1.655 billion to $1.680 billion, and adjusted EPS guidance is reaffirmed at $2.19 to $2.29 per share.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance